NFlection Therapeutics Inc.

Joseph Suttner brings more than 20 years of experience in drug development across the biotechnology and pharmaceutical industries. He specializes in global clinical operations, rare disease programs, and late-stage development. Before joining NFlection, S

Preclinical data and results of Phase 2a clinical study published in Science Advances First-in-human study demonstrated an excellent safety profile and potential therapeutic benefit for cutaneous neurofibromas based on biomarker and early clinical endpoin

The post NFlection Therapeutics Announces Positive Results from Phase 2b Study of NFX-179 Topical Gel in the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 appeared first on NFlection Therapeutics.

The post Novel Drug, NFX-179, Inhibits MEK Activity, Prevents Cutaneous Squamous Cell Carcinoma Development appeared first on NFlection Therapeutics.

Dr. Kenneth Tsai, M.D., Ph.D., is a board-certified dermatologist and dermatopathologist leading a NIH funded research program focused on cutaneous squamous cell carcinoma, signaling pathways in melanoma and responses to therapy, and biomarker development

Dr. Lu Le, M.D., Ph.D., received his Ph.D. in Microbiology, Immunology and Molecular Genetics, and his M.D. from the Medical Scientist Training Program at the University of California, Los Angeles. He completed an Internship in Internal Medicine at UCLA/S

Amy Paller, M.S., M.D., is the Walter J. Hamlin Professor and Chair, Professor of Pediatrics, and Director of the NIH-funded Skin Disease Research Center at Northwestern University's Feinberg School of Medicine. She received her undergraduate and graduate

Barbara Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS), respectively. In 1977 Dr. Gilchrest joined the Department of Dermatology and Division on Aging

Kavita Sarin, M.D., Ph.D., is an Associate Professor of Dermatology at Stanford University. She received her undergraduate degree in computer science, graduate degree in genetics and medical degree at Stanford University. She subsequently remained at Stan

Scott is a Professor of Neurology, Harvard Medical School, and Director, Neurofibromatosis Clinic, Massachusetts General Hospital(MGH). Scott is also Chief of Neuro-Oncology at MGH. He provides clinical care for patients with NF1, NF2, Scwhannomatosis and